KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Acadia Pharmaceuticals (ACAD) Assets: 2009-2025

Historic Assets for Acadia Pharmaceuticals (ACAD) over the last 17 years, with Sep 2025 value amounting to $1.3 billion.

  • Acadia Pharmaceuticals' Assets rose 36.23% to $1.3 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.3 billion, marking a year-over-year increase of 36.23%. This contributed to the annual value of $1.2 billion for FY2024, which is 58.59% up from last year.
  • Latest data reveals that Acadia Pharmaceuticals reported Assets of $1.3 billion as of Q3 2025, which was up 8.59% from $1.2 billion recorded in Q2 2025.
  • Acadia Pharmaceuticals' Assets' 5-year high stood at $1.3 billion during Q3 2025, with a 5-year trough of $587.8 million in Q4 2022.
  • Moreover, its 3-year median value for Assets was $914.1 million (2024), whereas its average is $936.6 million.
  • As far as peak fluctuations go, Acadia Pharmaceuticals' Assets decreased by 17.34% in 2022, and later surged by 58.59% in 2024.
  • Quarterly analysis of 5 years shows Acadia Pharmaceuticals' Assets stood at $700.1 million in 2021, then dropped by 16.04% to $587.8 million in 2022, then climbed by 27.41% to $749.0 million in 2023, then skyrocketed by 58.59% to $1.2 billion in 2024, then surged by 36.23% to $1.3 billion in 2025.
  • Its Assets was $1.3 billion in Q3 2025, compared to $1.2 billion in Q2 2025 and $1.1 billion in Q1 2025.